Fmr LLC Grows Holdings in CytomX Therapeutics, Inc. (CTMX)

Fmr LLC grew its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 0.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,512,459 shares of the biotechnology company’s stock after buying an additional 34,732 shares during the period. Fmr LLC owned approximately 15.00% of CytomX Therapeutics worth $85,444,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. boosted its stake in shares of CytomX Therapeutics by 1.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 292 shares in the last quarter. American International Group Inc. raised its holdings in CytomX Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 834 shares during the last quarter. Legal & General Group Plc raised its holdings in CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares during the last quarter. Teachers Advisors LLC raised its holdings in CytomX Therapeutics by 6.7% during the 4th quarter. Teachers Advisors LLC now owns 34,961 shares of the biotechnology company’s stock valued at $384,000 after buying an additional 2,209 shares during the last quarter. Finally, Swiss National Bank raised its holdings in CytomX Therapeutics by 19.1% during the 1st quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock valued at $463,000 after buying an additional 4,300 shares during the last quarter. 59.97% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Fmr LLC Grows Holdings in CytomX Therapeutics, Inc. (CTMX)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/12/fmr-llc-grows-holdings-in-cytomx-therapeutics-inc-ctmx.html.

Several research analysts have commented on the stock. Wedbush assumed coverage on shares of CytomX Therapeutics in a report on Thursday, September 7th. They issued an “outperform” rating and a $26.00 price objective for the company. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. BidaskClub downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $32.67.

In other news, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total value of $37,500.00. Following the completion of the sale, the chief financial officer now owns 19,626 shares of the company’s stock, valued at $294,390. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Sean A. Mccarthy sold 4,781 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total value of $71,715.00. Following the completion of the sale, the insider now directly owns 9,026 shares of the company’s stock, valued at approximately $135,390. The disclosure for this sale can be found here. Insiders have sold 177,794 shares of company stock valued at $3,806,089 over the last 90 days. 4.70% of the stock is currently owned by insiders.

CytomX Therapeutics, Inc. (CTMX) opened at 21.68 on Thursday. The stock’s 50 day moving average price is $18.02 and its 200 day moving average price is $15.75. CytomX Therapeutics, Inc. has a 52 week low of $9.85 and a 52 week high of $24.67. The firm’s market capitalization is $799.28 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The firm had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. On average, equities analysts expect that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply